--- title: "Evidence: mitochondrial fatty-acid transport" description: "Acetyl-l-carnitine shows limited and potentially chance-driven benefits for global clinical impression in Alzheimer's disease, but no clear objective…" url: "https://magellanlongevity.com/study/s126.md" canonical: "https://magellanlongevity.com/study/s126.html" html: "https://magellanlongevity.com/study/s126.html" type: "study" study_key: "s126" journal: "Cochrane Database Syst Rev" year: 2003 pmid: "12804452" doi: "10.1002/14651858.CD003158" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Evidence: mitochondrial fatty-acid transport [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Evidence: mitochondrial fatty-acid transport **HTML version:** https://magellanlongevity.com/study/s126.html · **In the Magellan app:** https://magellanlongevity.com/#/study/s126 ## Citation | Field | Value | | --- | --- | | Journal | Cochrane Database Syst Rev | | Year | 2003 | | PMID | [12804452](https://pubmed.ncbi.nlm.nih.gov/12804452/) | | DOI | [10.1002/14651858.CD003158](https://doi.org/10.1002/14651858.CD003158) | | Study key | s126 | ## Takeaway Acetyl-l-carnitine shows limited and potentially chance-driven benefits for global clinical impression in Alzheimer's disease, but no clear objective benefits for cognition or function. ## The question Is Acetyl-l-carnitine (ALC) clinically effective in treating people with dementia? ## Hypothesis The efficacy of ALC in cognitive decline remains unclear, with early studies suggesting benefit and later, larger studies not supporting these findings. ## Methods This review identified 11 double-blind, randomized trials comparing ALC with placebo in people with Alzheimer's disease. Data were extracted and analyzed using Revman 4.1 software, primarily focusing on completers. Outcomes assessed included cognitive effects, severity of dementia, functional ability, and clinical global impression. ## Results Statistically significant treatment effects favoring ALC were observed at 12 and 24 weeks for the number of patients showing improvement as determined by Clinical Global Impression (OR 2.33 at 12 weeks, OR 3.91 at 24 weeks). However, no benefit was found at 52 weeks for Clinical Global Impression, nor for cognition, severity of dementia, or functional ability when measured continuously. There were no statistically significant differences in adverse events between ALC and placebo groups. ## Conclusion There is some evidence for ALC's benefit on clinical global impression, but no evidence from objective assessments in other outcome areas. The statistically significant results might be due to chance given the number of comparisons. Currently, there is no evidence to recommend ALC's routine use in clinical practice for dementia. ## Limitations All included trials focused only on Alzheimer's disease, not other types of dementia. Methodological differences and assessment tools varied widely across early and later studies, making comparisons difficult. The statistically significant findings for clinical global impression might be due to chance given the multiple comparisons. The review primarily used completers' data rather than intention-to-treat. ## Verbatim from the abstract > There is evidence for benefit of acetyl-L-carnitine on clinical global impression ## Odds Ratio for Improvement by Clinical Global Impression with ALC | Measure | Odds Ratio | | --- | --- | | 12 Weeks | 2.33 | | 24 Weeks | 3.91 | *Odds ratios for improvement as determined by Clinical Global Impression, favoring Acetyl-l-carnitine over placebo at 12 and 24 weeks.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Acetyl-L-Carnitine (ALCAR) | Moderate evidence | [Acetyl-L-Carnitine (ALCAR)](https://magellanlongevity.com/p/126.md) | | L-Carnitine | Moderate evidence | [L-Carnitine](https://magellanlongevity.com/p/135.md) | ## Reference 1. **Evidence: mitochondrial fatty-acid transport** Cochrane Database Syst Rev 2003 · [PMID 12804452](https://pubmed.ncbi.nlm.nih.gov/12804452/) · [DOI 10.1002/14651858.CD003158](https://doi.org/10.1002/14651858.CD003158) > There is evidence for benefit of acetyl-L-carnitine on clinical global impression ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/s126.html#page","url":"https://magellanlongevity.com/study/s126.html","name":"Evidence: mitochondrial fatty-acid transport","description":"Acetyl-l-carnitine shows limited and potentially chance-driven benefits for global clinical impression in Alzheimer's disease, but no clear objective…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/s126.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Evidence: mitochondrial fatty-acid transport","item":"https://magellanlongevity.com/study/s126.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/s126.html#study","name":"Evidence: mitochondrial fatty-acid transport","headline":"Evidence: mitochondrial fatty-acid transport","datePublished":"2003","isPartOf":{"@type":"Periodical","name":"Cochrane Database Syst Rev"},"identifier":"PMID:12804452","url":"https://pubmed.ncbi.nlm.nih.gov/12804452/","sameAs":"https://doi.org/10.1002/14651858.CD003158","abstract":"Acetyl-l-carnitine shows limited and potentially chance-driven benefits for global clinical impression in Alzheimer's disease, but no clear objective benefits for cognition or function."}]} ``` ## Related on Magellan Longevity - [Acetyl-L-Carnitine (ALCAR)](https://magellanlongevity.com/p/126.md) — product graded on this and related evidence - [L-Carnitine](https://magellanlongevity.com/p/135.md) — product graded on this and related evidence - [Acetyl-L-carnitine Slows the Progression from Prefrailty to Frailty in Older Subjects: A…](https://magellanlongevity.com/study/d36043711.md) - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).